Karyopharm Therapeutics Debt Financing Update
Karyopharm Therapeutics has extended its existing Forbearance Agreement and Limited Waiver to Indentures from October 22, 2026, to November 1, 2026. This extension provides the company additional time to address its debt obligations while lenders agree to refrain from exercising certain rights or remedies during this period.
- Term
- through Nov 1, 2026